Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC

Akira Asai, Yusuke Tsuchimoto, Hideko Ohama, Shinya Fukunishi, Yasuhiro Tsuda, Makiko Kobayashi, Kazuhide Higuchi, Fujio Suzuki

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Despite major advances in curative and palliative approaches, hepatocellular carcinoma (HCC) is still the third leading cause of cancer-related death worldwide. M1 macrophages (Mφ) play a key role in host antitumor defenses in HCC. In our study, CD14+ cells were isolated from the peripheral blood of four groups of HCC patients (group-1, patients with stage 0 HCC; group-2, patients with stage A HCC; group-3, patients with stage B HCC; and group-4, patients with stage C HCC) and characterized phenotypically. Then, CD14+ cells from group-2 and group-3 HCC patients were induced to polarize and tested for their antitumor abilities in a chimera model of HCC patients. Human HCCs (HepG2 solid tumors) grew in a chimera model of group-3 patients (group-3 HCC chimeras) but not in a chimera model of group-2 patients (group-2 HCC chimeras). In response to HCC antigens, the majority of CD14+ cells from group-2 patients (group-2 CD14+ cells) switched to the M1 phenotype (IL-12+IL-10iNOS+cells), whereas the majority of CD14+ cells from group-3 patients (group-3 CD14+ cells) did not switch to the M1 phenotype and continued to express M2b phenotypic properties (IL-12IL-10+CCL1+iNOScells). Group-3 CD14+ cells showed M1Mφ polarization after treatment with CCL1 antisense oligodeoxynucleotide (ODN). Therefore, our study indicates that anti-HCC defenses of group-3 HCC chimeras are improved after CCL1 antisense ODN treatment.

Original languageEnglish (US)
Article numbere1299301
JournalOncoImmunology
Volume6
Issue number4
DOIs
StatePublished - Apr 3 2017

Fingerprint

Hepatocellular Carcinoma
Macrophages
Oligodeoxyribonucleotides
CD14 Antigens
Phenotype
Interleukin-12
Blood Group Antigens
Interleukin-10
Neoplasms

Keywords

  • Antisense oligodexynuclotide
  • CCL1
  • hepatocellular carcinoma
  • host antitumor resistance
  • macrophage

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC. / Asai, Akira; Tsuchimoto, Yusuke; Ohama, Hideko; Fukunishi, Shinya; Tsuda, Yasuhiro; Kobayashi, Makiko; Higuchi, Kazuhide; Suzuki, Fujio.

In: OncoImmunology, Vol. 6, No. 4, e1299301, 03.04.2017.

Research output: Contribution to journalArticle

Asai, A, Tsuchimoto, Y, Ohama, H, Fukunishi, S, Tsuda, Y, Kobayashi, M, Higuchi, K & Suzuki, F 2017, 'Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC', OncoImmunology, vol. 6, no. 4, e1299301. https://doi.org/10.1080/2162402X.2017.1299301
Asai, Akira ; Tsuchimoto, Yusuke ; Ohama, Hideko ; Fukunishi, Shinya ; Tsuda, Yasuhiro ; Kobayashi, Makiko ; Higuchi, Kazuhide ; Suzuki, Fujio. / Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC. In: OncoImmunology. 2017 ; Vol. 6, No. 4.
@article{bc27df99756f40b8862e27762942e9ff,
title = "Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC",
abstract = "Despite major advances in curative and palliative approaches, hepatocellular carcinoma (HCC) is still the third leading cause of cancer-related death worldwide. M1 macrophages (Mφ) play a key role in host antitumor defenses in HCC. In our study, CD14+ cells were isolated from the peripheral blood of four groups of HCC patients (group-1, patients with stage 0 HCC; group-2, patients with stage A HCC; group-3, patients with stage B HCC; and group-4, patients with stage C HCC) and characterized phenotypically. Then, CD14+ cells from group-2 and group-3 HCC patients were induced to polarize and tested for their antitumor abilities in a chimera model of HCC patients. Human HCCs (HepG2 solid tumors) grew in a chimera model of group-3 patients (group-3 HCC chimeras) but not in a chimera model of group-2 patients (group-2 HCC chimeras). In response to HCC antigens, the majority of CD14+ cells from group-2 patients (group-2 CD14+ cells) switched to the M1 phenotype (IL-12+IL-10−iNOS+cells), whereas the majority of CD14+ cells from group-3 patients (group-3 CD14+ cells) did not switch to the M1 phenotype and continued to express M2b phenotypic properties (IL-12−IL-10+CCL1+iNOS−cells). Group-3 CD14+ cells showed M1Mφ polarization after treatment with CCL1 antisense oligodeoxynucleotide (ODN). Therefore, our study indicates that anti-HCC defenses of group-3 HCC chimeras are improved after CCL1 antisense ODN treatment.",
keywords = "Antisense oligodexynuclotide, CCL1, hepatocellular carcinoma, host antitumor resistance, macrophage",
author = "Akira Asai and Yusuke Tsuchimoto and Hideko Ohama and Shinya Fukunishi and Yasuhiro Tsuda and Makiko Kobayashi and Kazuhide Higuchi and Fujio Suzuki",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/2162402X.2017.1299301",
language = "English (US)",
volume = "6",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "4",

}

TY - JOUR

T1 - Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC

AU - Asai, Akira

AU - Tsuchimoto, Yusuke

AU - Ohama, Hideko

AU - Fukunishi, Shinya

AU - Tsuda, Yasuhiro

AU - Kobayashi, Makiko

AU - Higuchi, Kazuhide

AU - Suzuki, Fujio

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Despite major advances in curative and palliative approaches, hepatocellular carcinoma (HCC) is still the third leading cause of cancer-related death worldwide. M1 macrophages (Mφ) play a key role in host antitumor defenses in HCC. In our study, CD14+ cells were isolated from the peripheral blood of four groups of HCC patients (group-1, patients with stage 0 HCC; group-2, patients with stage A HCC; group-3, patients with stage B HCC; and group-4, patients with stage C HCC) and characterized phenotypically. Then, CD14+ cells from group-2 and group-3 HCC patients were induced to polarize and tested for their antitumor abilities in a chimera model of HCC patients. Human HCCs (HepG2 solid tumors) grew in a chimera model of group-3 patients (group-3 HCC chimeras) but not in a chimera model of group-2 patients (group-2 HCC chimeras). In response to HCC antigens, the majority of CD14+ cells from group-2 patients (group-2 CD14+ cells) switched to the M1 phenotype (IL-12+IL-10−iNOS+cells), whereas the majority of CD14+ cells from group-3 patients (group-3 CD14+ cells) did not switch to the M1 phenotype and continued to express M2b phenotypic properties (IL-12−IL-10+CCL1+iNOS−cells). Group-3 CD14+ cells showed M1Mφ polarization after treatment with CCL1 antisense oligodeoxynucleotide (ODN). Therefore, our study indicates that anti-HCC defenses of group-3 HCC chimeras are improved after CCL1 antisense ODN treatment.

AB - Despite major advances in curative and palliative approaches, hepatocellular carcinoma (HCC) is still the third leading cause of cancer-related death worldwide. M1 macrophages (Mφ) play a key role in host antitumor defenses in HCC. In our study, CD14+ cells were isolated from the peripheral blood of four groups of HCC patients (group-1, patients with stage 0 HCC; group-2, patients with stage A HCC; group-3, patients with stage B HCC; and group-4, patients with stage C HCC) and characterized phenotypically. Then, CD14+ cells from group-2 and group-3 HCC patients were induced to polarize and tested for their antitumor abilities in a chimera model of HCC patients. Human HCCs (HepG2 solid tumors) grew in a chimera model of group-3 patients (group-3 HCC chimeras) but not in a chimera model of group-2 patients (group-2 HCC chimeras). In response to HCC antigens, the majority of CD14+ cells from group-2 patients (group-2 CD14+ cells) switched to the M1 phenotype (IL-12+IL-10−iNOS+cells), whereas the majority of CD14+ cells from group-3 patients (group-3 CD14+ cells) did not switch to the M1 phenotype and continued to express M2b phenotypic properties (IL-12−IL-10+CCL1+iNOS−cells). Group-3 CD14+ cells showed M1Mφ polarization after treatment with CCL1 antisense oligodeoxynucleotide (ODN). Therefore, our study indicates that anti-HCC defenses of group-3 HCC chimeras are improved after CCL1 antisense ODN treatment.

KW - Antisense oligodexynuclotide

KW - CCL1

KW - hepatocellular carcinoma

KW - host antitumor resistance

KW - macrophage

UR - http://www.scopus.com/inward/record.url?scp=85018280246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018280246&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2017.1299301

DO - 10.1080/2162402X.2017.1299301

M3 - Article

VL - 6

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 4

M1 - e1299301

ER -